What is your process for assessing the "high risk" clinical features in gBRCA+ breast cancer in order to offer olaparib, given varying definitions of risk and recent changes in staging guidelines?

Topics: Breast Cancer • Medical Oncology • Journal Club ft. NEJM publications • BRCA+ • Breast Cancer, Non-metastatic

Definitions for "high risk" differ by whether patients receive neoadjuvant chemo and across other contemporary studies. Does the change in AJCC staging from V7 to V8 impact patient selection for adjuvant treatment?

Answer from: Medical Oncologist at Academic Institution

I follow the criteria used in the eligibility for the OlympiA trial to determine who I will offer olaparib to in the adjuvant setting, which is consistent with the ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.In patients with gBRCA+ breast cancer who received at least 6 cycles...

Comments

Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology
Do you feel this is a reason to give NAC to T1cNo ...

Answer from: Medical Oncologist at Academic Institution

I would use the eligibility criteria used in OlympiA study for HR positive patients.

Answer from: Medical Oncologist at Academic Institution

The definition of high risk clinical features varies across clinical trials. Most patients with triple negative breast cancers are considered high risk for recurrence and hence chemotherapy is usually indicated. Among hormone receptor positive breast cancer, patients with high genomic risk, high Ki-...

Related Questions